Patrys Limited (PAB.AX)

AUD 0.0

(0.0%)

Market Cap (In AUD)

8.22 Million

Revenue (In AUD)

1.39 Million

Net Income (In AUD)

-3.53 Million

Avg. Volume

670.22 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.003-0.01
PE
-
EPS
-
Beta Value
0.558
ISIN
AU000000PAB9
CUSIP
Q7322A105
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James A. Campbell B.Sc., MBA, Ph.D.
Employee Count
-
Website
https://www.patrys.com
Ipo Date
2007-07-13
Details
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.